News
Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid-19 patients
Nafamostat has been identified as a potential candidate for Covid-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany
